PharmaEssentia Corporation PharmaEssentia Corporation

PharmaEssentia Corporation

6446

Classificação em ações #1418
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Preço da ação
$37.84
Valor de mercado
$15.65B
Variação (1 dia)
-4.42%
Variação (1 ano)
149.23%
País
TW
Negociar PharmaEssentia Corporation (6446)

Categoria

Healthcare
Histórico de dividendos de PharmaEssentia Corporation (6446)
PharmaEssentia Corporation (símbolo da ação: 6446) realizou um total de 1 pagamentos de dividendos.
A soma de todos os dividendos (ajustada para desdobramentos de ações) é: $0.99
Rendimento de dividendos (TTM): 0.0012
Pagamentos de dividendos de PharmaEssentia Corporation (6446) de 2025 a 2026
Pagamentos anuais de dividendos
Ano Dividendo (ajustado para desdobramentos) Alterar
2026 (TTM) $0.9898 0.00%
2025 $0.9898 0.00%
Lista de todos os pagamentos de dividendos
Ano Dividendo Alterar
2026 (TTM) $1.10 0.00%
2025 $1.10 0.00%
Dividendos de empresas semelhantes ou concorrentes